DIA Bioventure Day

Is the current Bioventure paradigm delivering return for patients and investors? This is the key question to be addressed by stakeholders from the funding, and from the innovating side.

Back to Agenda

Session 2: Innovative Funding Models

Speaker(s)

Ritchie Head

Director, Ceratium Limited, United Kingdom

Joep Muijrers

Chief Financial Officer, PureTech Health, United States

Funding Private and Public Enterprises

Oliver Mahr

Investment & Fintech Hub Manager, Deutsche Boerse Venture Network, Germany

The German Stock Exchange Venture Network

Dimitrios Athanasiou, MBA

Patient Advocate , WORLD DUCHENNE ORGANIZATION (WDO) , MDA HELLAS, Greece

Megafunds: Concept Introduction & Discussion

Have an account?